Once Weekly Insulins - A Paradigm Change for Basal Insulin Replacement

QWINT: A Paradigm Shift in Insulin Therapy In this episode, Harpreet Bajaj, Carol Wysham, and Richard Bergenstal explore the revolutionary QWINT program, a once-weekly insulin therapy currently in development. With a unique mechanism of action resulting in a 17-day half-life, QWINT has the potential to transform diabetes care by reducing the treatment burden for patients and caregivers alike. The discussion covers key findings from the program’s trials, including strong patient preference despite challenges in type 1 diabetes management, and highlights the benefits for older patients and those requiring assistance with daily activities. Join us to learn how QWINT is poised to redefine insulin therapy and improve the quality of life for people living with diabetes.